4basebio PLC (LON:4BB – Get Free Report)’s share price dropped 3.4% during mid-day trading on Thursday . The company traded as low as GBX 420 and last traded at GBX 420. Approximately 79 shares traded hands during trading, a decline of 95% from the average daily volume of 1,599 shares. The stock had previously closed at GBX 435.
4basebio Stock Performance
The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The company’s fifty day simple moving average is GBX 501.30 and its two-hundred day simple moving average is GBX 590.56. The stock has a market cap of £65.04 million, a price-to-earnings ratio of -4.24 and a beta of 1.09.
Insiders Place Their Bets
In other 4basebio news, insider Amy Walker acquired 2,650 shares of the stock in a transaction on Friday, February 13th. The shares were purchased at an average price of GBX 586 per share, for a total transaction of £15,529. Insiders own 12.07% of the company’s stock.
4basebio Company Profile
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Featured Stories
- Five stocks we like better than 4basebio
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
